License and Option. (i) MARSHFIELD CLINIC hereby grants to Licensee under the Licensed Patents an exclusive license to make, use and sell Products in the Licensed Field and Licensed Territory.
License and Option. (a) Subject to the terms and conditions of this Agreement, Xencor hereby grants to Amgen an exclusive, royalty-bearing license, with the right to sublicense through multiple tiers, under the Xencor Technology and Xencor’s interest in the Joint Patents, to Develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory (the “License”), which License shall be in effect during the Term but shall be exercisable only in the event that Amgen provides the Option Exercise Notice and pays Xencor the Initial Option Exercise Fee. The License shall be exclusive even as to Xencor, except that Xencor retains the right during the Collaboration Period to conduct Development activities of the Compound and Product (other than those activities expressly allocated to Amgen) in accordance with the Pre-POC Development Plan under Section 3.2.
License and Option. University grants to Company an exclusive option to obtain an exclusive (if available) worldwide license, with the right to grant sublicenses in the case of an exclusive license, to any or all of University's interests in the University Inventions and Joint Inventions under this Agreement. The terms of the exclusive license will be negotiated in good faith by the Parties, such option to exist for ninety (90) days following Company’s receipt of disclosure of such Invention. Such license will include commercially reasonable financial consideration, including reimbursement of patent costs.
License and Option. You and your institution grant to JHU (I) a non-exclusive royalty-free license to Inventions for non-commercial academic research purposes (ii) a non-exclusive, royalty bearing (not to exceed 1% of JHU's licensee's net sales) transferable license to Inventions which are new uses of the Material(s) (for example, new therapeutic indications for, and new methods of administration of, the Material(s) and (iii) a first option to obtain an exclusive, royalty-bearing transferable license to any or all of your interests in the Inventions, all with the right to grant sublicenses. For each Invention, JHU's first option must be exercised within ninety (90) days of your disclosure of that Invention to JHU. The royalty payable to you and other terms of the exclusive license will be negotiated by the parties in good faith.
License and Option. A. Institution certifies to its reasonable knowledge at the time of signing this Program Agreement that subject to any retained rights of any relevant government entity, it has the right to grant and Institution shall grant an exclusive option to Lilly, but which grant is conditioned upon Institution at its sole discretion providing Lilly the Chemical Structure for the Material pursuant to a Structure Reveal Letter, and also subject to Section XII, PUBLICATION. The exclusive option shall be for the right to negotiate an agreement including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of Material (collectively the “Research Opportunities”). The option shall expire sixty (60) days (the “Option Period”) after Lilly has received the Chemical Structure for the subject Material from Institution pursuant to a Structure Reveal Letter. The option may be exercised by Lilly in writing at any time prior to its expiration. The option period may be extended by mutual written agreement of the parties. Any agreement executed pursuant to the exercise of the option granted hereunder shall be negotiated in good faith within one hundred eighty (180) days (the “Negotiation Period”) after Lilly has exercised the option. The Negotiation Period may be extended by mutual agreement of the parties as long as they continue negotiating in good faith. The parties acknowledge that if Institution elects not to submit the Chemical Structure, or if the parties have not completed a compound purchase, license or collaboration agreement within the Negotiation Period (or any extension thereof), then the option no longer exists and Institution shall have no further obligations to Lilly with respect to the Material.
License and Option. 6. Recipient hereby grants to Provider a non-exclusive, royalty-free, worldwide license, to each Recipient Sole Invention. Recipient hereby grants to Provider an option to obtain an exclusive worldwide license, to each Recipient Sole Invention and to Recipient’s interest in any Joint Inventions, on commercially reasonable terms. The option shall extend for a period of nine (9) months following disclosure of the Invention to Provider. License terms will be negotiated in good faith. In the event the parties fail to reach a mutually acceptable agreement within twelve (12) months after commencing negotiations, Recipient shall be entitled to negotiate a license with a third party for such Invention.
License and Option. 3.1 FHCRC hereby grants to LICENSEE a royalty-bearing, exclusive (except as otherwise stated herein) license under FHCRC’s entire interest in the PATENT RIGHTS to manufacture, have manufactured, distribute, have distributed, use, research, improve, import and export, offer to SELL and SELL LICENSED PRODUCTS within the LICENSED TERRITORY for use within the LICENSED FIELD. FHCRC also grants to LICENSEE a non-exclusive license to the TECHNOLOGY RIGHTS for the same purposes and scope as is specified for the license of the PATENT RIGHTS. Subject to the terms hereof, LICENSEE may practice such licenses itself or through its SUBLICENSEES. These grants are subject to the Government of the United States of America as described in Sections 14.1 and 14.2 of this AGREEMENT, the timely payment by LICENSEE to FHCRC of all consideration due hereunder from LICENSEE as provided herein, and the following rights retained by FHCRC to:
License and Option. Recipient and Investigator- grant to GI (a) a non--exclusive, royalty--fee license to Inventions' which arc new uses of the Material (for example, new therapeutic indications for, and new methods of manufacture and administration of the Material) and (b) a first option to obtain an exclusive, royalty--bearing license to ;any or all of Recipient's and Investigator's interests in the Inventions, both with the right to grant sublicenses. For each Invention. GI's first option must be exercised within ninety (90) days of full written disclosure of that Invention to GI by Recipient and/or Investigator. The royalty payable to Recipient or Investigator and other terms of the exclusive license will be negotiated in good faith.
License and Option. In further consideration for the assignment and license of rights to the Technology hereunder, Company hereby grants back to Assignor a non-exclusive, perpetual, worldwide (excluding the Republic of Korea) royalty-free transferable license (with the right to sublicense through multiple tiers of sublicenses) to make, have made, use, sell, offer for sale, import, copy, reproduce, distribute and practice the Assigned Technology assigned or licensed to Company hereunder; provided that if Company shall fail to commercialize the Assigned Technology and the license to the Licensed Technology in any country within five (5) years of the Effective Date, then at Assignor's sole option, ownership of the Assignor Technology with respect to that particular country shall revert to Assignor. For purposes of implementing this Section 6, on or about forty-eight (48) months after Effective Date, Company shall provide to Assignor a report detailing Company's progress in the commercialization of the Assigned and Licensed Technology and shall thereafter supply to Assignor such information as reasonably requested by Assignor, to demonstrate Company's commercialization obligations as set forth in this Section 6. The license granted back to Assignor in this Section 6 shall survive, in the event of the bankruptcy of Company.
License and Option. 4.1 BOARD hereby grants to LICENSEE a royalty-bearing, exclusive worldwide license under LICENSED SUBJECT MATTER to manufacture, have manufactured, import, use, offer for SALE and/or SELL LICENSED PRODUCTS for use within FIELD. This grant is subject to the payment by LICENSEE to BOARD of all consideration as provided herein, and is further subject to rights retained by BOARD to:
